ÂÜÀòÂÒÂ×

Scott is co-founder and CEO of Comanche Biopharma, a private company developing novel siRNA compounds to treat preeclampsia. Prior to Comanche, Scott was a co-founder of The Medicines Company where he served as director (1996-2009) until he joined the management team as chief medical advisor (2009-2021). In that role, he was responsible for evaluating the company’s long-range global strategy and for the licensing or acquisition of innovative products, including inclisiran, for which the company was purchased by Novartis.

Previously, Scott was a founding General Partner at JSB Partners, L.P., an investment bank with a focus on mergers and acquisitions, private financings and corporate alliances within the healthcare sector. From September 1991 to July 1999, Scott served as a founder and managing director of MPM Capital, LLC, a venture capital firm.

Scott holds a B.S. in chemistry (Phi Beta Kappa) and an M.D. (Alpha Omega Alpha) from the University of Alabama. His academic career included faculty positions at Harvard Medical School, the University of Colorado Medical School, and the University of South Alabama. He has been Board Certified in Internal Medicine, Pulmonary and Critical Care Medicine and Sleep Disorders Medicine. He currently is Chairman, Board of Directors, MaxiVAX SA, a biopharmaceutical company focused on immuno-oncology.